Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2008

View Archived Issues

Novel transglycosylase inhibitors with antibacterial activity discovered

Eisai updates Q3 progress

Intercell to develop tuberculosis vaccine formulated with adjuvant IC-31

FDA accepts Y's Therapeutics' IND application to conduct a phase I clinical trial of YSCMA

Fornix reports results from phase II/III AB0602 clinical study of Oralgen

DiaMedica reports positive results from preclinical study of DM-99

Pharmaxis to apply for MAA in Australia for Bronchitol for the treatment of bronchiectasis

Alvine initiates dosing in phase I clinical trial of ALV-003 for celiac disease

New therapeutic agents for urinary incontinence imparted in recent Takeda patents

Recent patents report new agents for neurological disorders

Novel analgesic agents described in recent patent literature

AstraZeneca announces creation of a new company Albireo

Biogen Idec and Cardiokine initiate a phase III study of lixivaptan

DelSite initiates production of clinical quantities of nasal powder bird flu vaccine

TorreyPines presents 2008 strategic plan for tezampanel, NGX-426, and NGX-267

Migenix provides pipeline update

Neuroprotective effects of lithium in preclinical and clinical studies of ALS

VRX-496 affects HIV replication in phase II trial

Activity of RDEA-806 less affected by human serum proteins than other NNRTIs

Improved body composition seen with tesamorelin in HIV-associated lipohypertrophy

FDA approves Abbott's Simcor, a combination therapy for cholesterol management

Vaccinex licenses human anti-interleukin-6 antibody to GlaxoSmithKline

JADO reports proof of concept with lipid raft modulator in atopic dermatitis patients

Canada approves Wellbutrin XL for prevention of seasonal major depressive illness

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...